Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
This randomized phase II trial studies how well mucoadhesive oral wound rinse works in preventing and treating stomatitis in patients with estrogen receptor (ER)- or progesterone receptor (PR)-positive metastatic or locally recurrent breast cancer that cannot be removed by surgery receiving everolimus. Mucoadhesive oral wound rinse may help prevent symptoms of stomatitis, or mouth sores, in patients receiving everolimus.
Estrogen Receptor-positive Breast Cancer
HER2-negative Breast Cancer
Progesterone Receptor-positive Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Drug: mucoadhesive oral wound rinse
Other: laboratory biomarker analysis
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
|Official Title:||Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.|
- Rate of grades 1-4 stomatitis assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 [ Time Frame: Up to 7 days after completion of treatment ] [ Designated as safety issue: No ]Will be estimated and the 95% confidence interval (CI) will also be obtained. Chi-square test will be used to compare the stomatitis rates between the two study arms.
- Rate of grade 3/4 stomatitis assessed using CTCAE version 4.03 [ Time Frame: Up to 7 days after completion of treatment ] [ Designated as safety issue: No ]Will be estimated and the 95% CI will also be obtained. Chi-square test will be used to compare the stomatitis rates between the two study arms.
- Rate of everolimus dose adjustment or discontinuation related to stomatitis [ Time Frame: Up to 7 days after completion of treatment ] [ Designated as safety issue: No ]
|Study Start Date:||February 2015|
|Estimated Primary Completion Date:||February 2017 (Final data collection date for primary outcome measure)|
Experimental: Arm I (mucoadhesive oral wound rinse)
Patients receive mucoadhesive oral wound rinse PO as a gentle swish for 30-60 seconds 3-6 times daily beginning on day 1 of everolimus therapy and continuing for up to 6 months in the absence of unacceptable toxicity.
Drug: mucoadhesive oral wound rinse
Other Names:Other: laboratory biomarker analysis
No Intervention: Arm II (no intervention)
Patients receive no intervention.
I. Evaluate whether use of prophylactic MuGard (mucoadhesive oral wound rinse) in participants being treated with everolimus will reduce the rate of stomatitis.
I. Compare symptoms from mouth sores in patients receiving MuGard compared with those receiving best supportive care.
II. Evaluate the rate of everolimus dose adjustment or therapy discontinuation as a result of stomatitis in participants treated with MuGard prophylaxis versus best supportive care.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive mucoadhesive oral wound rinse orally (PO) as a gentle swish for 30-60 seconds 3-6 times daily beginning on day 1 of everolimus therapy and continuing for up to 6 months in the absence of unacceptable toxicity.
ARM II: Patients receive no intervention.
After completion of study treatment, patients are followed up within 7 days.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02015559
|United States, California|
|Jonsson Comprehensive Cancer Center||Not yet recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Parvin Peddi 310-206-8477 email@example.com|
|Principal Investigator: Parvin Peddi|
|Principal Investigator:||Parvin Peddi||Jonsson Comprehensive Cancer Center|